Lumateperone (ITI-722; ITI722; Caplyta) is a novel, potent, first-in-class and dual 5HT2A receptor antagonist and dopamine receptor phosphoprotein modulator (DPPM). IT is a butyrophenone atypical antipsychotic approved in 2019 for the treatment of schizophrenia, and is currently under development for bipolar depression and other neurological indications.

纯度：≥98%

CAS：313368-91-1